Neurizon Therapeutics Limited has released a press release.
OLE Study update reveals impressive Survival Data
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- Executive team strengthened, appointment of MD/CEO & new CSO
- PharmAust receives Orphan Drug Designation for monepantel
- Board Changes
- Resignation of Dr Michael Thurn & appointment of John Clark
- Final Ethics Approval for Open-Label MND Extension Study
Later from Neurizon Therapeutics
- PharmAust raises $10 million via Placement and announces SPP
- Share Purchase Plan Offer Booklet
- Monepantel Selected for Entry into HEALEY ALS Platform Trial
- PharmAust Completes Share Purchase Plan
- Positive Interim Study Results from OLE Study in ALS
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics